Intarcia snags $200M for yearlong diabetes minipump in PhIII; Alnylam gets orphan status positive opinion in Europe;

> Intarcia pulled in $200 million for its Phase III exenatide minipump designed to deliver the drug to diabetes patients over the course of a year. Story

> The European Medicines Agency gave Alnylam ($ALNY) a positive opinion regarding the orphan status of the company's ALN-TTRsc RNAi drug for patients with transthyretin-mediated amyloidosis. Release

> Particle Sciences entered a development agreement with Actavis ($ACT) for an unnamed generic product using one of Particle's many delivery technologies. Release

> Ablative Solutions won FDA clearance for its Peregrine infusion catheter designed to deliver drugs directly to the perivascular layer surrounding the blood vessels. Release

> Biolight filed an IND with the FDA for a Phase I/IIa study of its glaucoma implant with controlled release of latanaprost. Release